Trial reportInternational journal of hematology2017
Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study.
Trial report in International journal of hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04600960 (Eltrombopag for Chemotherapy-induced Thrombocytopenia), which is not on this map. Cited by 35 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Eltrombopag for Chemotherapy-induced Thrombocytopenia: a Prospective Multi-center One-arm Study in Solid Tumors
Who cites it
35 citing papers in PubMed, 5 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- The efficacy and safety of thrombopoietin receptor agonists in solid tumors with chemotherapy-induced thrombocytopenia: a systematic review and network meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2025Pooled it
- Efficacy and safety of different treatments in chemotherapy-induced thrombocytopenia: a systematic review and network meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Efficacy and safety of thrombopoietin receptor agonists in solid tumors with chemotherapy-induced thrombocytopenia: a meta-analysis.BMC pharmacology & toxicology · 2023Pooled it
- Systematic literature review and meta-analysis on use of Thrombopoietic agents for chemotherapy-induced thrombocytopenia.PloS one · 2022Pooled it
- Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours.The Cochrane database of systematic reviews · 2017Pooled it
- Efficacy and safety of eltrombopag in the treatment of cancer therapy-induced thrombocytopenia: a large-scale, multicenter, retrospective study in China.Blood science (Baltimore, Md.) · 2026Article
- Advances and Clinical Applications of Thrombopoietic Agents.Current medical science · 2026Review
- Eltrombopag for Chemotherapy-Induced Thrombocytopenia: A Multicenter Retrospective Real-World Study.Hematology reports · 2026Article
- The evolving landscape of platelet therapy: risks, innovations, and clinical judgment.Annals of hematology · 2026Review
- Hetrombopag for thrombocytopenia induced by concurrent or sequential chemoradiotherapy in patients with solid tumors: a double-cohort trial.BMC cancer · 2025Article
- Understanding Chemotherapy-Induced Thrombocytopenia: Implications for Gastrointestinal Cancer Treatment.Current oncology (Toronto, Ont.) · 2025Review
- Chemotherapy-induced thrombocytopenia: modern diagnosis and treatment.British journal of haematology · 2025Review
- Efficacy and safety of hetrombopag in the treatment of chemotherapy-related thrombocytopenia in solid tumors: a retrospective study.Frontiers in oncology · 2025Article
- Cancer treatment-induced thrombocytopenia: diagnosis, mechanisms and management.Frontiers in immunology · 2025Review
- Avatrombopag for the treatment of patients with chemotherapy-induced thrombocytopenia: A case series.British journal of haematology · 2025Article
- Romiplostim in chemotherapy-induced thrombocytopenia: A review of the literature.Cancer medicine · 2024Review
- Article
- Hetrombopag for the management of chemotherapy-induced thrombocytopenia in patients with advanced solid tumors: a multicenter, randomized, double-blind, placebo-controlled, phase II study.Therapeutic advances in medical oncology · 2024Article
- Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists.Blood reviews · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this phase 2 study, patients with solid tumors receiving gemcitabine monotherapy or gemcitabine plus cisplatin/carboplatin were randomized 2:1 to eltrombopag 100 mg (n = 52) or placebo (n = 23) for 5 days before and after chemotherapy was started. The primary endpoint was prechemotherapy (Day 1) platelet count across ≤6 cycles. Prechemotherapy platelet counts were numerically higher with eltrombopag than placebo. Frequencies of grades 3/4 thrombocytopenia were lower with eltrombopag in both the combination therapy (77 vs. 100%) and monotherapy (36 vs. 42%) groups. Proportionately fewer eltrombopag-treated patients had platelet counts <100 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.